Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

INTRODUCTION: An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. METHODS: Patients were treated every 3 or 4 weeks with 254–1029 mg/kg/infusion of IVIG. RESULTS: Overall, Biotest-IVIG infusions were well t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wasserman, Richard L., Church, Joseph A., Stein, Mark, Moy, James, White, Martha, Strausbaugh, Steven, Schroeder, Harry, Ballow, Mark, Harris, James, Melamed, Isaac, Elkayam, David, Lumry, William, Suez, Daniel, Rehman, Syed M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3389237/
https://ncbi.nlm.nih.gov/pubmed/22392046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-012-9656-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak